279 Midpark Way S.E.
AB T2X 1M2
Canada - Map
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.
|Mr. Donald J. McCaffrey ,
Co-Founder, Chief Exec. Officer, Pres, Sec. and Director
|Mr. Aaron Brad Cann C.A., CBV,
Chief Financial Officer
|Dr. Norman C. W. Wong B.Sc (Hon), M.Sc, M.D., FRCP,
Co-Founder, Chairman of the Scientific Advisory Board and Chief Scientific Officer
|Dr. Henrik C. Hansen ,
VP of Intellectual Property & Technology Devel.
| Sarah Zapotichny ,
Director of Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|